Home » Pipeline
Pipeline
September 16, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Selvita | SEL120 | acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) | Phase 1b trial initiated enrolling subjects at sites across the U.S. |
| VBI Vaccines Inc. | VBI-1901 in combination with GlaxoSmithKline’s proprietary AS01B adjuvant system | recurrent glioblastoma (GBM) | Phase 2a trial initiated enrolling 20 subjects with first-recurrent GBM only |
| Recardio, Inc. | dutogliptin in combination with filgrastim | post-myocardial infarction | Phase 2 trial initiated enrolling 140 subjects at specialized cardiology centers located throughout Europe and the U.S. |
| Alector, Inc. | AL001 | frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN) | Phase 2 trial initiated enrolling 32 subjects with FTD-GRN and an additional cohort of FTD subjects with a C9orf72 mutation (FTD-C9orf72) |
| Biohaven Pharma Holding Company Ltd. | vazegepant | acute treatment of migraine | Phase 2/3 trial initiated |
| Lipidor AB | Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01) | mild to moderate psoriasis | Phase 3 study initiated enrolling 277 subjects at 14 clinics across India |
| Functional Neuromodulation | fornix (DBS-f) | mild Alzheimer's Disease | Phase 3 study initiated enrolling 210 people 65 years or older with mild Alzheimer's disease at 14 study sites in the U.S., Canada and Germany |
| EMD Serono | evobrutinib | relapsing multiple sclerosis (RMS) | Two phase 3 studies initiated enrolling 1,900 adult subjects |
| Nevakar Inc. | NVK-002 | slow the progression of myopia in children | Phase 3 study initiated enrolling 576 child subjects aged 3 to 17 years in Asia, the U.S. and Europe |
| Netech | Delta 3300 | arrhythmia | 510(k) approval granted by the FDA |
| Merck KGaA | tepotinib | metastatic non-small cell lung cancer (NSCLC) | Breakthrough Therapy Designation granted by the FDA |
| Horizon Therapeutics plc | teprotumumab | active thyroid eye disease (TED) | Priority Review granted by the FDA |
| Almirall LLC | Aczone 7.5% topical gel | acne vulgaris | Approval granted by the FDA |
| Jenkins Eye Care | AcrySof IQ PanOptix Trifocal Intraocular Lens (IOL) | cataract | Approval granted by the FDA |
| Axonics Modulation Technologies, Inc. | implantable rechargeable sacral neuromodulation (“SNM”) device | urinary and bowel dysfunction | Approval granted by the FDA |
| Boehringer Ingelheim Pharmaceuticals | Ofev (nintedanib) capsules | interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD) | Approval granted by the FDA |
